Killer immunoglobulin-like receptor (KIR) and KIR–ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2

NK cells play a role in many cancer immunotherapies. NK cell activity is tightly regulated by killer immunoglobulin-like receptor (KIR) and KIR–ligand interactions. Inhibitory KIR–ligands have been identified as HLA molecules, while activating KIR–ligands are largely unknown. Individuals that have n...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Immunol Immunother
Autors principals: Wang, Wei, Erbe, Amy K., Gallenberger, Mikayla, Kim, KyungMann, Carmichael, Lakeesha, Hess, Dustin, Mendonca, Eneida A., Song, Yiqiang, Hank, Jacquelyn A., Cheng, Su-Chun, Signoretti, Sabina, Atkins, Michael, Carlson, Alexander, Weiss, Jonathan M., Mier, James, Panka, David, McDermott, David F., Sondel, Paul M.
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5123674/
https://ncbi.nlm.nih.gov/pubmed/27695964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-016-1904-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars